Answers are grounded in this paper and cite their sources.
Retrospective analysis shows that CD19 polymorphism affects treatment outcomes in mantle cell lymphoma, indicating potential for risk stratification.
Background: Brexu-cel is an established CD19-directed CAR-T cell therapy for relapsed or refractory mantle cell lymphoma, but clinical outcomes are heterogeneous, and germline determinants of response are poorly defined. Methods: We investigated the clinical impact of the CD19 single-nucleotide polymorphism rs2904880 on treatment outcome after brexu-cel CAR-T cell therapy by analyzing genotype-outcome associations in a retrospective single-center cohort of patients with relapsed or refractory mantle cell lymphoma treated with this CAR-T cell therapy. Results: Overall survival varied according to CD19 polymorphism, with improved survival of patients carrying the V174 homozygous genotype compared with L174V heterozygotes. Conclusions: The germline CD19 polymorphism may have implications for future risk stratification after brexu-cel CAR-T cell therapy in mantle cell lymphoma, but requires validation in larger, multicenter cohorts.
No takes yet. Share an insight, caveat, or question.
Ruckstuhl et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: